Comparison of the effect of cilostazol and traditional antiplatelet drugs for preventing thromboembolic complications during coil embolization for unruptured intracranial aneurysms

Comparison of the effect of cilostazol and traditional antiplatelet drugs for preventing thromboembolic complications during coil embolization for unruptured intracranial aneurysms - Cilostazol study of coil embolization for unruptured intracranial aneurysms

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008570

Enrollment

100

Registered

2012-09-01

Start date

2013-07-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unruptured intracranial aneurysms

Interventions

Patients administered cilostazol Patients administered aspirine or clopidogrel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Unruptured intracranial aneurysms measuring 4 to 10 mm and Dome to Neck ratio is 1.5 or more.

Exclusion criteria

Exclusion criteria: Patients with contraindication of either cilostazl, aspirin or clopidogrel. Patients expecting pregnancy

Design outcomes

Primary

Measure	Time frame
The risk of thromboembolic complications	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026